Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.19.3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 10, 2015
Oct. 31, 2019
Jul. 31, 2019
May 30, 2019
Mar. 28, 2019
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Nov. 20, 2015
Oct. 19, 2015
Consulting and scientific advisory board agreement description             : (i) two advisory board members shall be issued common stock equivalent to $5,000 the last day of such quarter when meetings are held (ii) one consultant shall receive common stock equivalent to $6,250 on the last day of each month and (ii) one consultant shall receive a renumeration amount of $10,000-$12,000 per month with an earn out potential of 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals based on certain factors.                  
Common stock shares issued for services             33,588 7,500                
Lease expiry date             Jun. 30, 2019                  
Research and development expenses           $ 123,910 $ 123,910                  
Office Equipment [Member]                                
Total royalty payable $ 405,000                              
Deposit amount                             $ 55,000  
Cancellation of secured promissory note                               $ 55,000
Payables to the Company 295,000         96,120 96,120       $ 96,120          
Payables to Alpine Creek $ 1,215,000         $ 27,800 $ 27,800                  
Payable commitment description In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories           On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale.                  
Payable per treatment sold $ 100                              
Profit holding percentage 50.00%                              
Minimum [Member]                                
Development and expansion expenses amount             $ 3,000,000                  
Maximum [Member]                                
Consideration amount       $ 2,760,000                        
January 22, 2019 [Member]                                
Beginning balance, Shares         200,000                      
January 1, 2019 [Member]                                
Subscription and royalty agreement description         Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”)                      
Description for the use of proceeds under agreement         The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development                      
BioCorRx, Inc [Member] | BioCorRx Pharmaceuticals, Inc [Member]                                
Beginning balance, Shares         200,000                      
Common Stock [Member]                                
Beginning balance, Shares           5,299,184 5,299,184 2,532,863 3,057,848 3,030,124 2,597,347 2,471,863 2,471,113 2,440,863    
Common stock shares issued for services   2,162 1,658                          
Common Stock, Subscribed                                
Compensation for services           $ 12,500                  
Beginning balance, Shares                              
Additional Paid-In Capital                                
Compensation for services             15,833                  
Beginning balance, Shares                              
Accumulated Deficit                                
Compensation for services             15,000                  
Common stock issuable value             $ 5,000